Original Research ARTICLE
Patients with drug-naïve bipolar disorder in remission after eight weeks of treatment had decreased serum uric acid concentrations
- 1Beijing HuiLongGuan Hospital, Peking University, China
- 2School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Australia
- 3School of Medicine, University of Wollongong, Australia
- 4Illawarra Health and Medical Research Institute, University of Wollongong, Australia
Evidence indicates that the serum concentration of uric acid (UA) in patients may relate both to the pathophysiology and therapeutics of bipolar disorder (BPD). The purpose of this study was to examine the changes and clinical significance of serum UA concentrations in first-episode manic patients suffering from BPD.
Seventy-six drug-naive patients with first-episode bipolar mania and seventy-six age- and gender- matched healthy subjects were recruited. Young Mania Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS) were used to assess clinical symptoms. We tested serum UA concentrations by sandwich enzyme-linked immunosorbent assay (ELISA) at baseline and at the end of 8-week treatment in BPD patients and in the control group.
After 8-week quetiapine and sodium valproate therapy, the concentrations of serum UA were significantly decreased compared to the pre-therapy baseline levels (t=3.361, p<0.001). Concentrations of UA were significant lower in remitted group than non-remitted group (t=2.07, p=0.04). There was a significant correlation between the changes of UA concentrations and their YMRS scores (r = 0.25, p = 0.03). Patients suffering manic disorder had higher serum UA than those remitted patients (378.55±99.08 vs. 323.57± 73.53 μmmol/L, p<0.001). All BPD patients had higher serum UA concentrations than healthy subjects (293.39±71.40 μmmol/L, all p<0.05).
Our results suggested that serum UA concentrations might present not only a biomarker of the state of mania, but also potentially a trait marker in bipolar patients. It could be a significant biomarker objectively estimating the treatment efficacy in patients suffering from BPD.
Keywords: Therapeutic effecacy, Depression, mania, Hyperuricaemia, bipolar disorder
Received: 09 May 2019;
Accepted: 24 Sep 2019.
Copyright: © 2019 Chen, Chen, Zhang, Tan, Wang, Jones, Yang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Xu-Feng Huang, University of Wollongong, School of Medicine, Wollongong, 2522, New South Wales, Australia, firstname.lastname@example.org